



# PRESS RELEASE

Thursday, 27<sup>th</sup> October 2016, Mumbai

## **GlaxoSmithKline Pharmaceuticals Limited announces a 12% Sales growth for the quarter ended 30 September, 2016**

---

**GlaxoSmithKline Pharmaceuticals Limited** today declared its financial results for the quarter ended 30<sup>th</sup> September 2016. Sales for the quarter ended 30<sup>th</sup> September 2016 came in at Rs.783 crores, recording a growth of 12% as compared to the same prior year period. Profit from Operations at Rs. 134 crores increased by 9% against the same prior year period and diluted by mandatory price cuts.

Profit Before Tax (PBT) at Rs.152 crores and Profit After Tax (PAT) at Rs 99 crores grew by 4% and 3%, respectively, against the same prior year period, predominantly impacted by mandatory price cuts as well as a decline in Other Income.

Commenting on the results, **A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

“The strong performance of pharmaceuticals in Q2 highlights the momentum of the company with a volume growth of 16%. This translates to a diluted value growth of 13% caused by the recent mandated price revisions. Our key brands continue to underpin the growth performance of the Company.

During the quarter, the Company successfully launched Priorix-Tetra®, a combined measles, mumps, rubella and varicella vaccine.

Our ongoing capital investment programme at our state-of-the art manufacturing site at Vemgal, Bengaluru remains on track as part of meeting the future market demand. The capital investments as well as a reduction in interest rates drive a reduction in Investment Income contributing to a PAT growth of 3% as compared to the same prior year quarter.”

### **About GlaxoSmithKline Pharmaceuticals Limited**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com)

Media Contacts:  
Ransom D'Souza  
Head - Corporate Communications  
Email: [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)  
Tel: +91 22 24959203